Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis.
about
The evolution of poxvirus vaccinesImmunization against Leishmania major infection using LACK- and IL-12-expressing Lactococcus lactis induces delay in footpad swellingCytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasisClinical and parasitological protection in a Leishmania infantum-macaque model vaccinated with adenovirus and the recombinant A2 antigenCytokine responses to novel antigens in a peri-urban population in Brazil exposed to Leishmania infantum chagasi.Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice.TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia)Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular ApproachesHigh quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection.Vaccination with L. infantum chagasi nucleosomal histones confers protection against new world cutaneous leishmaniasis caused by Leishmania braziliensis.Antigenicity and protective efficacy of a Leishmania amastigote-specific protein, member of the super-oxygenase family, against visceral leishmaniasis.Development of Vaccines against Visceral LeishmaniasisCoadministration of the Three Antigenic Leishmania infantum Poly (A) Binding Proteins as a DNA Vaccine Induces Protection against Leishmania major Infection in BALB/c MiceHeterologous priming-boosting with DNA and modified vaccinia virus Ankara expressing tryparedoxin peroxidase promotes long-term memory against Leishmania major in susceptible BALB/c MiceKilled but metabolically active Leishmania infantum as a novel whole-cell vaccine for visceral leishmaniasis.Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11Identification of Leishmania infantum chagasi proteins in urine of patients with visceral leishmaniasis: a promising antigen discovery approach of vaccine candidates.Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against LeishmaniaDNA Vaccines against Protozoan Parasites: Advances and ChallengesDNA vaccination with KMP11 and Lutzomyia longipalpis salivary protein protects hamsters against visceral leishmaniasisDNA vaccine against visceral leishmaniasis: a promising approach for prevention and control.Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis.Head-to-head comparison of three vaccination strategies based on DNA and raw insect-derived recombinant proteins against Leishmania.Previous exposure to a low infectious dose of Leishmania major exacerbates infection with Leishmania infantum in the susceptible BALB/c mouse.Construction of a Novel DNA Vaccine Candidate encoding LmSTI1-PpSP42 Fusion Protein from and Against Cutaneous LeishmaniasiSearching Genes Encoding Leishmania Antigens for Diagnosis and Protection
P2860
Q26995905-AA18F732-5ACC-4865-AB98-8EBA8AAC8034Q28480593-1C550E14-1227-47FE-ABEF-B5E39591F93FQ28485121-000C2889-A498-4CAA-AF6C-C89B1B60FF26Q28539852-CE629072-19E2-44C7-A1BB-B3E179D76E75Q30416865-950163EF-E510-410C-A7F7-E82CA9BD951AQ33818084-E316C5C6-94AA-4372-99CC-AC71546F3B2DQ33939303-580231BB-6885-4A40-B14F-2E56E8D7F466Q34076804-5D12C34C-901C-45BB-ABB3-81F22A1DE613Q34310410-4A58351A-F2DE-48D7-986B-1F86BA3AAF34Q34533591-6F2DEA08-257A-4F59-BD7B-53E890CA3619Q34662190-6C52D953-48F4-4565-BADA-B33B190D2CCDQ35207606-0DF0577E-EA22-4884-B15D-A8D4A573E91AQ35587034-322B4B19-3D3F-48B4-BFEC-D1F5FB36991FQ35689200-5E8B1341-AD0C-43A4-ADCC-86CE9E31B2C9Q35867177-1E53ED67-3607-4A98-84B5-D1E78ADBA653Q35972642-3CDF0C0E-9EA9-45CB-9744-1445E50F3C51Q36105743-A3D27ED9-20CC-470A-ACAE-5B9D3C2A3255Q36251325-77E0351C-E43E-45B5-99E0-38D3863945F5Q36915067-40633FAC-E273-4E43-8876-3E621E2DAD31Q37106270-16EFA792-B5D2-4B9B-93BB-1BCA9915CE9BQ38786910-D96F50DF-FB40-4A69-A11C-5162303934EAQ39313487-BA8F8CBC-4265-4A35-9D78-A963B8BFAEDFQ41404819-11BAFBD3-D531-4A1F-A2F6-D8E9B9D05950Q44218777-69C5AF2A-6D66-4AE5-B7F4-713C49A760A7Q57489047-2DB81280-3B45-4728-99BE-7E7D6C4EBA9BQ58647150-43502A8F-8C44-4D2A-993C-249FF985EA9D
P2860
Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Heterologous prime-boost vacci ...... murine visceral leishmaniasis.
@en
Heterologous prime-boost vacci ...... murine visceral leishmaniasis.
@nl
type
label
Heterologous prime-boost vacci ...... murine visceral leishmaniasis.
@en
Heterologous prime-boost vacci ...... murine visceral leishmaniasis.
@nl
prefLabel
Heterologous prime-boost vacci ...... murine visceral leishmaniasis.
@en
Heterologous prime-boost vacci ...... murine visceral leishmaniasis.
@nl
P2093
P2860
P1476
Heterologous prime-boost vacci ...... murine visceral leishmaniasis.
@en
P2093
Blaise Dondji
Diane McMahon-Pratt
Eva Pérez-Jimenez
Karen Goldsmith-Pestana
Mariano Esteban
P2860
P304
P356
10.1128/IAI.73.8.5286-5289.2005
P407
P577
2005-08-01T00:00:00Z